UMB creates position to encourage research, industry partnerships
Simeon Taylor, MD, PhD, a
seasoned pharmaceutical executive who has served in senior positions
with Eli Lilly and Co. and Bristol-Myers Squibb, has joined the University of Maryland, Baltimore (UMB)
as industry liaison with its Center
for Clinical Trials and Corporate Contracts (CCT).
In his new role for CCT, he will assist faculty in developing research
strategies that will maximize corporate partnering and funding
opportunities, and the possible creation of valuable intellectual
property. CCT is part of the University's Office of Research and Development,
and the part-time consultancy is funded in keeping with the
"We are delighted to add Simeon to CCT's business development
team. We created the industry liaison position to maximize our
corporate partnering and funding opportunities with the hope that this
research may lead to new, valuable intellectual property," says Michael Rollor, PhD, MBA, assistant
vice president at CCT.
"Simeon understands the academic research environment and is also able
to provide valuable insights and contacts drawn directly from his
experience as a pharmaceutical executive," Rollor says.
Taylor brings experience in both industry and government. In 1979, he
went to the U.S. National Institutes of Health, where he was chief of
the Diabetes Branch from 1989 to 2000. At NIH, his research focused on
mechanisms of insulin resistance, genetics of insulin resistant
diabetes, and devising innovative therapies including metreleptin to
treat lipoatrophic diabetes.
His contributions were recognized with the Outstanding Service Award of
the U.S. Public Health Service and the Outstanding Scientific
Achievement Award of the American Diabetes Association.
In 2000, Taylor moved to the pharmaceutical industry. In his role
as vice president of cardiovascular and metabolic disease research at
Bristol-Myers Squibb, he made substantial contributions to research and
development, leading to three approved drugs: saxagliptin,
dapagliflozin, and apixaban.
Most recently, he has returned to academia as an adjunct professor in
the Division of Endocrinology, Diabetes and Nutrition at the
University of Maryland School
Taylor received his education at Harvard University (BA, MD, and PhD)
and his clinical training at Massachusetts General Hospital (Internal
Medicine and Endocrinology).
|Posting Date: 05/30/2014
|Contact Name: Patricia Fanning
|Contact Phone: 410-706-7946
|Contact Email: email@example.com